Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
MKM Lowers Fair Value, Adjusts Estimates on Amarin (AMRN) Following Q1 Results
May 12, 2014 12:19 PM EDTMKM Partners is lowering its fair value estimate on Amarin (Nasdaq: AMRN) from $2 down to $1.50, while maintaining the stock at Neutral.
Analyst Jon LeCroy commented, Vascepa prescriptions are again growing and the Kowa co-promote, scheduled to begin this month, is... More
UPDATE: Citi Downgrades Amarin Corporation (AMRN) to Neutral
May 12, 2014 6:42 AM EDT(Updated - May 12, 2014 10:07 AM EDT)
Citi downgraded Amarin Corporation (NASDAQ: AMRN) from Buy to Neutral with a price target of $1.75. Analyst Jonathan Eckard thinks shares will trade range-bound near-term.
"We are downgrading AMRN to Neutral from Buy, finding it harder to see when Vascepa sales could turn a corner to drive support back to the stock. Dragging sales... More
Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
May 9, 2014 7:03 AM EDTAmarin Corp Plc (NASDAQ: AMRN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.65 million.
Operational update
Commercialization and regulatory update
Amarin is now available on formulary to over 200 million lives in the United States, including over 100 million with Tier 2 coverage. As the company works to continue to increase the productivity of our sales representatives and work with our new co-promotion partner, Kowa Pharmaceuticals America, the company believes Vascepa sales will continue to... More
